Navigation Links
Virobay Completes $8 Million Series B Preferred Stock Financing
Date:7/16/2014

MENLO PARK, Calif., July 16, 2014 /PRNewswire/ -- Virobay, Inc., a clinical stage pharmaceutical company with a platform of cathepsin protease inhibitors being developed for the treatment of neuropathic pain, autoimmune disease and fibrosis, today announced the closing of an expanded Series B second tranche financing of $8.0 million. Including this recent $8 million investment, Virobay has raised an aggregate of $18 million in two tranches of the Series B financing.  The first tranche was drawn in 2010.  Participants in the second tranche transaction include a syndicate of existing investors plus Perceptive Advisors, a dedicated healthcare fund.  Existing investors include TPG Biotechnology Partners, Alta Partners, Sutter Hill Ventures and Abbvie, Inc.  Additional terms of the financing were not disclosed.

Virobay expects to use proceeds from this offering to advance its clinical programs forward, specifically the clinical development of its lead product candidate, VBY-036, for the treatment of neuropathic pain.

"We are pleased that Perceptive Advisors joined our distinguished list of investors, and in addition, we appreciate the continued support of our existing investors," commented Dr. Robert Booth, President and Chief Executive Officer of Virobay. 

About Virobay

Virobay is focused on the development and commercialization of novel drugs through the utilization of small molecule cysteine proteases inhibitors, a diverse class of enzyme proteases, for a variety of conditions, including neuropathic pain, autoimmune diseases and fibrosis.  The foundation of Virobay's proprietary cathepsin platform and the Virobay management team were spun-out from Celera Genomics, which was then a leader in cathepsin research. Virobay's clinical pipeline currently includes product candidates in neuropathic pain, dermatology, autoimmune disease and fibrosis.  For more information please visit our website: www.virobayinc.com.

Contact:

Jim Welch
Chief Financial Officer
(650) 833-5715
jim.welch@virobayinc.com


'/>"/>
SOURCE Virobay, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Virobay and LEO Pharma Initiate a Phase 1 Trial of VBY-891, a Compound Intended for Oral Treatment of Psoriasis
2. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
3. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
4. NuMe Health Completes $1.5 Million Series A Financing To Advance Its First Cobiotic™ Aimed At Helping Prediabetics Maintain Healthy Blood Glucose Levels
5. CryoLife Completes Acquisition of Hemosphere
6. Bausch + Lomb Completes the Acquisition of ISTA Pharmaceuticals
7. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
8. Jazz Pharmaceuticals Completes EUSA Pharma Acquisition
9. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
10. Ablative Solutions Completes $5.3M Series A Financing
11. Quantum OPS Completes $1.05M In Series A Financing To Advance Surgical Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 2016 , Net Sales of $1.90 billion ... the prior year period, and an increase of 1.2% on ... EPS for the first quarter were $0.52 reported, a decrease ... an increase of 29.9% over the prior year period ... guidance for 2016 Zimmer Biomet Holdings, Inc. (NYSE ...
(Date:4/28/2016)... , April 28, 2016 Oramed ... a clinical-stage pharmaceutical company focused on the development of oral ... in the upcoming PIONEERS 2016 conference, presented by Joseph ... 2016 in New York . Nadav ... at the conference. Presentation Details:   ...
(Date:4/28/2016)... April 28, 2016  ValGenesis, Inc., the ... Solutions (VLMS) today announced that a prominent ... sufferers of chronic kidney failure has selected ... their corporate validation process. The global medical ... solution to manage their validation processes electronically. ...
Breaking Medicine Technology:
(Date:4/30/2016)... , ... April 30, 2016 , ... ... Studios. With inMotion3D Abstract users can distort and manipulate three-dimensional shapes with ease ... rotation, columns, rows, ranks, point, lines, polygons, polygon texture animation, opacity texture animation, ...
(Date:4/30/2016)... ... April 30, 2016 , ... ... News on April 4th, 2016 questioned the use of the HyProCure sinus ... as “a controversial procedure.” EOTTS-HyProCure is a minimally invasive procedure performed, when ...
(Date:4/29/2016)... ... ... In an article published April 16th on the New York ... injections, which she underwent in order to feel more at home at this year’s ... article explains that Ms. Mirmelli’s situation is not unique; many plastic surgeons say they’ve ...
(Date:4/29/2016)... ... ... On Tuesday, April 26, 2016 members of the HomeTown Health network, a network ... on SB 258, the “Rural Health Care Relief” Bill. , The bill, which was ... individuals and corporations which donate directly to a “rural hospital” in Georgia, and goes ...
(Date:4/29/2016)... ... April 29, 2016 , ... Coast Dental Fort Stewart ... at its new location in the Exchange Furniture Mall at 112 Vilseck Road in ... 50-inch Samsung Smart TV. Plus attendees will have the opportunity to meet general dentists ...
Breaking Medicine News(10 mins):